Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Beovu 120 mg/ml solution for injection in pre-filled syringe

Active Ingredient:
brolucizumab
Company:  
Novartis Pharmaceuticals UK Ltd See contact details
ATC code: 
S01LA06
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs Audio/Video Live Chat HCP Med Info
{arrow_left}
{arrow_right}
Audio Guide to Beovu - Click on the PLAY button to listen, or right click to save the audio file. To view or download a text version see the 'Risk Materials' tab.
Beovu Patient Guide to Therapy - Audio Version
This audio has been produced by Novartis Pharmaceutical Limited. Your guide to therapy with Beovu (brolucizumab) – for the treatment of neovascular (wet) age-related macular degeneration (AMD).


Beovu Patient Guide to Therapy - for patients with visual impairment due to DMO
This audio has been produced by Novartis Pharmaceutical Limited. Your guide to therapy with Beovu (brolucizumab) – for the treatment of patients with visual impairment due to Diabetic Macular Oedema (DMO).


Novartis Pharmaceuticals UK Ltd
Company image
Address
2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
Telephone
+44 (0)1276 692 255
Medical Information Direct Line
+44 (0)1276 698 370
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)845 741 9442
E-mail
[email protected]